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Abstract
Early experiments in womb transplants have increased interest in the possibility of per-
forming this procedure in women who have no womb, usually for congenital reasons. The 
present article describes past experiments and summarises the most relevant reference 
documents before indicating the key ethical implications involved in womb transplants.
INTRODUCTION
Clinical and ethical considerations do not apply 
equally to all the organs that can be transplanted in hu-
mans. While some organs are vital for survival (heart, 
liver, lung), others that are not necessary for survival 
nonetheless raise ethical, anthropological and emo-
tional issues that involve not only – and in any case to a 
lesser degree – the physical well-being of the recipient, 
but also the perception of the self and of one’s body.
While a hand or face transplant clearly does not 
constitute a life-saving procedure, both imply signifi-
cant problems regarding the patient’s self-perception. 
The present article concerns womb transplants which, 
because of the particular importance of the womb in 
female reproductive functions, belongs to the same cat-
egory. A womb is the place where a new human being 
settles, is formed and develops, invisible to the world 
until an ultra-sound reveals it and perceived as growing 
only by the woman who carries it: a womb transplant 
– involving only women – is thus the only “gender trans-
plant” performed to date.
We are, therefore, not talking about the usual bioethi-
cal problems that accompany new methods of medically 
assisted procreation (such as the beginning of a person’s 
life or the moral status of the embryo), but rather about 
the symbolic value attached to the womb. Although the 
present article addresses the problem from the point of 
view of the state of the art of the procedure in clinical 
terms and in regard to the more typically bioethical is-
sues involved in transplants in general, it is nonethe-
less important to keep in mind the peculiarities of the 
womb, its functioning and purpose, that are unique 
characteristics.
Womb transplants were performed in animals as long 
ago as the 1960s [1]; in humans they have to date been 
performed in women born without a uterus (Mayer-
Rokitansky-Kunster-Hauser), but could be appropriate 
for other pathologies that involve the uterus.
The first experimental womb transplant in a woman 
was performed in 2000 [2]. The uterus was taken from 
a 46-year old living donor and transplanted into a 26-
year old woman. It responded to treatment with oestro-
gen and progesterone and could thus potentially have 
been stimulated to achieve endometrial proliferation. 
However, the development of thrombosis in the anas-
tomosed blood vessels led to necrosis of the graft and it 
had to be removed.
A second attempt was made in 2011 in Turkey [3]. 
A 20-year old woman received a uterus taken from a 
deceased donor of the same age. Twenty days later the 
patient had her first menstrual cycle, which was fol-
lowed by two early spontaneous abortions following two 
embryo transfers.
In 2012-2013 the first clinical trial was conducted, 
involving eight women with uterine agenesis and one 
who had had a hysterectomy [4, 5]. The organs were re-
moved from living donors, in most cases the mothers of 
the recipients. Post-operative complications included: 
thrombosis in the uterine arteries (1 case in 9) pleural 
effusion (2/9), intrauterine abscess (1/9) retroperito-
neal haematoma (1/9). The only post-operative com-
plication in a donor was one case of urethral-vaginal 
fistula (1/9). Two of the transplants were unsuccessful: 
bilateral uterine artery occlusion and persistent endo-
metriosis required hysterectomy. In the remaining cases 
menstrual cycles were regular after 6 months.
In 2013, at the Sahlgrenska University Hospital in Go-
thenburg (Sweden), a 35-year old women suffering from 
Rokitansky syndrome was given a womb taken from a 
living 65-year old donor. Prior to the transplant in vitro 
fertilisation had been performed using oocytes from the 
recipient and spermatozoa from her partner, and 11 em-
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bryos had been frozen. Forty-three days after the trans-
plant the recipient had her first menstruation and one 
year after the first embryo was transplanted. After 31 
weeks and 6 days the woman gave birth to a boy of nor-
mal weight for his gestational age [6]. Subsequently, the 
transplants in Sweden resulted in four other births [7, 8].
Table 1 shows a summary of the womb transplants re-
ported to date in the specialised literature.
Although New York’s Downtown Hospital had an-
nounced plans to perform a womb transplant in January 
2007 [9], the first operation was performed on 24th Feb-
ruary 2016 in Cleveland. The recipient was a 26-year 
old who had been included in an experimental trial aim-
ing for 10 transplants, and the womb was taken from a 
deceased 30-year old donor (in contrast to the Swedish 
trial, which used living donors). On 8th March 2016 the 
transplanted womb had to be removed in an emergency 
operation, as a result of complications [10].
The Swedish cases encouraged several surgical teams 
in various countries to plan womb transplants. Such 
plans are usually announced in press conferences or 
through press agencies. For example:
• in France a womb transplant is planned for 2016 in 
Limoges [11];
• in Italy, the Ethical Committee of the Italian Health 
Institute has approved a womb transplant protocol at 
the Umberto I Hospital in Rome, in accordance with 
the regulations governing the authorisation of such tri-
als [12];
• in the United Kingdom the UK Womb Transplant 
Research Team led by Richard Smith, consultant gyn-
aecologist at Queen Charlotte’s and Chelsea Hospital 
in London, received authorisation in September 2015 
to conduct trials with 10 patients [13].
INSTITUTIONAL DOCUMENTS
In 2008 a report by the International Federation of 
Gynecology and Obstetrics (FIGO) found that the lack 
of sufficient data on the safety and efficacy for the re-
cipient meant that womb transplants were not accept-
able from the ethical point of view. The FIGO therefore 
made the following recommendations:
“1. uterine transplantation, which may reach human 
clinical experimentation stage, should only occur after 
significant and adequate research in appropriate large 
animal models, including primates;
2. the lengths to which some women will go to experi-
ence uterine transplantation, even with the availability 
of such options as adoption and surrogacy in some cul-
tures, can lead to a conflict of interest and pressure on 
researchers to move prematurely to human application;
3. ut is unethical to remove a uterus for transplantation 
from a young woman who did not complete having the 
desired number of children or a uterus with a deformed 
cavity;
4. given the lack of data on safety and the known haz-
ards to live donors, the procedure is considered ethi-
cally inappropriate” [14].
In 2012 a working group from McGill University 
(Montreal, Canada) proposed the “Montreal criteria 
for the ethical feasibility of uterine transplantation” 
[15], which were updated the following year [16]. The 
revised Montreal criteria for the ethical feasibility of 
uterine transplantation are:
1. The recipient 
a. is a genetic female of reproductive age with no medi-
cal contraindications to transplantation,
b. has documented congenital or acquired UFI that 
has failed all current gold standard and conservative 
therapy,
c. (c1) has a personal or legal contraindication to surro-
gacy and adoption measures and desires to have a child, 
or (c2) seeks the UTx solely as a measure to experience 
gestation, with an understanding of the limitations pro-
vided by the UTx in this respect,
d. has not had her decision to undergo UTx deemed as 
irrational by expert psychological evaluation, and has 
no psychological comorbidity that interferes with diag-
nostic workup or treatment,
e. does not exhibit frank unsuitability for motherhood,
f. is likely to take antirejection medication and follow 
up with the treating team in a responsible manner, and 
g. is responsible enough to consent, informed enough 
to make a responsible decision.
2. The donor
a. is a female of reproductive age with no medical con-
traindications to donation,
b. (b1) has repeatedly attested to her conclusion of par-
ity, or (b2) has signed an advanced directive for post 
mortem organ donation,
Table 1
Summary of the womb transplants reported to date in the specialised literature
Author N. patients Age Donor/s Outcome
Fageeh et al. [2] 1 26 living Hysterectomy for vascular  occlusion 3 months after 
transplant 
Ozkan et al. [3] 1 21 deceased Pregnancy and abortion
Brännström et al. [4]  
Johannesson et al. [5]  
Brännström et al. [6] 
Dahm-Kähler et al. [7]
Brännström et al. [8]
10 31.5 
(average)
living 7 cases: viable uterus (of which 3 with  
sub-clinical rejection treated effectively with 
corticosteroids)
2 cases: serious rejection with bilateral occlusion of 
arteries 
5 live births
Cleveland Clinic [10] 1 26 deceased Hysterectomy 12 days after transplant for 
complications
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c. has no history of uterine damage or disease, and
d. is responsible enough to consent, informed enough 
to make a responsible decision, and not under coercion.
3. The health care team
a. is part of an institution that meets Moore’s third cri-
terion as it pertains to institutional stability,
b. has provided adequate informed consent to both par-
ties regarding risks, potential sequelae, and chances of 
success and failure,
c. has no conflict of interest independently or with ei-
ther party, and
d. has the duty to preserve anonymity if the donor or 
recipient do not explicitly waive this right”.
On 23rd June 2015 the French Académie Nationale 
de Médecine published a report on “La transplanta-
tion uterine” [17]. The report noted the data published 
so far, and in particular those relating to the birth in 
Sweden in 2015; pointed to the uncertainties, risks and 
problems; noted that transplants from both living and 
deceased donors raised serious issues; indicated the un-
certainties surrounding the long-term health conditions 
of children born from a transplanted womb, and made 
the following recommendations:
“1. research programmes that are conducted strictly in 
accordance with regulations laid down in law and by the 
Agence de la Biomédecine in regard to all innovations 
in the matter of organ transplantations and medically 
assisted procreation should continue;
2. clear and detailed information that takes into ac-
count the drawbacks and risks associated with womb 
transplants should be given to living donors and recipi-
ents participating in these research programmes, who 
should be given appropriate assistance before, during 
and after the procedure;
3. data on research conducted in France and in other 
countries should be collected with a view to ensuring 
the validity of womb transplants and, in due course, to 
assess the possibility of extending the procedure, with 
respect for the ethical principles that apply in all organ 
transplantations and medically assisted procreation, in 
order to avoid deviations”.
More recent documents, as we can see, are less wary 
of the concept of womb transplants. However, the 
FIGO has still not amended the opinion it published in 
2008 [18], notwithstanding the availability of additional 
results.
ETHICAL ASPECTS
General criteria for experimental surgery
With very few exceptions new surgical techniques 
do not enter clinical practice as a result of randomised 
clinical trials; they evolve gradually from existing tech-
niques or, more rarely, from bold divergences from com-
mon practice adopted by a surgical team on the basis of 
experience [19].
Francis D. Moore has proposed three criteria that 
should be met in order for innovative surgical procedures 
to become acceptable, including from the ethical point 
of view. The first is laboratory experience that optimally 
should precede a surgical innovation; the second is “field 
strength” meaning the intellectual and technical exper-
tise available in the institution where the work is being 
done; and the third is “institutional stability” based on its 
resources, support systems, and staff [20, 21]. All three 
were cited in the “Montreal criteria for the ethical feasibil-
ity of uterine transplantation” mentioned above [15, 16].
Donation from deceased and living donors
There are pros and cons for transplants from de-
ceased donors:
Pros:
• no risk for the donor;
• less time needed for removal;
• technically easier, thanks to longer peduncles and 
easier anastomosis. 
Cons:
• difficult in making a complete pre-operative appraisal;
• logistic issues: distances, etc.;
• informed consent calls for special attention. When 
transplanting unusual organs (e.g. face, hands) it is ad-
visable to ask for specific consent in addition to the ge-
neric declaration of consent to the donation of organs 
[21]. This is particularly advisable before removing a 
womb, given the special significance and symbolic na-
ture of the organ;
• very little clinical exp erience;
• there are pros and cons for transplants from living 
donors.
Pros:
• increased certainty that the organ will function.
Cons:
• highly complicated procedure for the donor: Brän-
nström reported surgical procedures lasting more than 
10 hours, involving considerable risks [6];
• the age of living donors is a further problem. To in-
crease the chance of success the donor should be of 
childbearing age. It is clearly problematic, to say the 
least, to remove the womb of a fertile woman, even she 
has already born children; 
• it could be feasible to transplant a womb taken from 
a living donor with a pathology that does not directly 
involve the uterus (which therefore continues to func-
tion) but prevents her procreating;
• a particular problem arises with transsexual women 
who wish to have their wombs removed. The Acadé-
mie Nationale de Médecine has suggested that in these 
cases a womb transplant could be possible provided two 
conditions are met: the transplant should be performed 
in the interest of the transsexual and for the therapeutic 
benefit of the recipient (i.e. procreation) [17]. On this 
point it should be noted that some lesbian, gay, bisexu-
al, transsexual (LGBT) associations are campaigning to 
abolish the need for surgical sterilisation as a requisite 
for gender reassignment. Clearly, while such cases fall 
within the category of transplants from living donors, 
the unusual nature of the donor’s personal journey calls 
for an even more specific form of informed consent;
• current legislation requires that there should be a 
family connection between the donor and the recipient. 
Cases of undue influence (such as a mother who feels 
responsible for her daughter’s inability to procreate) 
and other forms of interference cannot be ruled out.
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The recipient
Although womb transplants are seen in some quar-
ters as being relatively simple in comparison with the 
transplantation of other organs, the procedure is a com-
plex one. The operation described by Brännström lasted 
10 hours and 7 minutes for the donor and 4 hours and 
55 minutes for the recipient [6].
A womb transplant is not a life-enhancing event for 
the recipient (in fact, it has the opposite effect), though 
it does enable her to procreate.
To avoid the need for lifelong immunosuppressive 
therapy, a womb transplant requires two further op-
erations: a caesarean section for delivery, followed by 
a hysterectomy.
The possibility of rejection during pregnancy means 
that an exit strategy is more complicated in a womb 
transplant than in other organ transplantation proce-
dures.
Issues of distributive justice also arise, given that the 
high costs of these interventions make them inacces-
sible to most people.
There is a considerable imbalance between the large 
number of potential recipients and very few potential 
donors. The main source should be young, brain-dead 
donors with healthy wombs, of whom there are very 
few.
Recipients should receive detailed information re-
garding: the surgical risks, probable need to remove the 
transplanted uterus, complex preparation process (pre-
operative hormone therapy), possible failure to procre-
ate and the effects of immunosuppressive therapy.
Womb transplants and medically-assisted procreation
The two are linked because to date post-transplant 
pregnancies have been initiated only after in vitro fer-
tilisation.
Womb transplants pose many problems similar to 
those posed by other assisted procreation procedures: 
rights of the donor, health consequences for the foetus 
and child, interventions on a woman’s body, the role of 
the state in regulating procreation, etc.
There are considerable regulatory problems. Current 
regulations in most states do not mention womb trans-
plants either in the context of assisted procreation or 
among types of transplants performed to date.
Womb transplants could be considered as a means to 
counter the perverse phenomenon of surrogacy, though 
in the current circumstances it is too experimental a 
procedure to be an alternative: this could change if and 
when womb transplants become a part of consolidated 
clinical practice. For the sake of clarity, the lack of a 
“medical” alternative to surrogacy does not make this 
phenomenon ethically legitimate; it remains an unac-
ceptable exploitation of women and a violation of the 
rights of the child. In the current state of knowledge the 
requisite cited in the “Montreal criteria for the ethical 
feasibility of uterine transplantation” – that the recipi-
ent should have “a personal or legal contraindication to 
surrogacy” – is ethically highly controversial and, in the 
authors’ opinion, quite unacceptable.
There could be a higher risk of trade in wombs than 
in other organs. This risk is heightened by the fact that 
while there exist international conventions against the 
trade in organs for transplantation [22] (which unfor-
tunately is nonetheless present in some states), some 
countries allow the legal sale of gametes. This, com-
bined with the current legalisation or, in some states, 
mild acceptance of surrogacy, could lead to the treat-
ment of the womb as a “separate” case associated with 
female reproduction, an area that is already more sus-
ceptible to market criteria and less protected.
Pregnancy
Because the objective of womb transplants is concep-
tion, these procedures pose highly specific problems 
linked to the wellbeing of the product of conception, 
that are not associated with the transplantation of other 
organs. In ethical terms the risks are of primary con-
cern.
Currently available figures do not point to short-term 
risks for the child as a consequence of immunosuppres-
sion, but risks associated with premature birth cannot 
be excluded, nor can long-term risks such as haemo-
philia, cancer, retarded growth or other pathologies.
There is the possibility of psychological risks for chil-
dren on learning they were born from a transplanted 
womb.
 
CONCLUSIONS
The transplantation of a womb is the first all-female 
“gender transplant” performed to date: it stands alone 
in the world of transplants, also because of the emo-
tional and symbolic importance attached to the func-
tioning and purpose of the womb. In ethical and clinical 
terms, it is the opinion of the authors that in the current 
state of knowledge womb transplants are still a highly 
experimental procedure and should be subject to all 
the risk/benefit assessments normally applied in simi-
lar circumstances. It should also be recalled that this is 
not a life-saving procedure and that the womb should 
in any case be removed after any pregnancy in order to 
permit the interruption of immunosuppressive therapy: 
the risk/benefit assessment should be performed in this 
light. The state of the art for the moment excludes the 
possibility that womb transplants can be considered as 
an alternative to other forms of pregnancy, which in 
any case are highly controversial in ethical, social and 
psychological terms (and unacceptable in the authors’ 
opinion), such as surrogacy, or even as an alternative 
to legitimate means of achieving parenthood such as 
adoption. In brief, in ethical terms womb transplants 
from a deceased donor, in specific, carefully controlled 
and clinically assessed circumstances and bearing in 
mind that such procedures are currently highly experi-
mental, could be acceptable, while the removal and 
transplantation of a womb from a living donor presents 
for now such major issues and contra-indications as to 
render it unacceptable.
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